Will be interesting the strategy once FDA reply comes in. Could it be a viable option to go for TGA approval first (Aust/NZ)? Conserves cash, creates revenue, gives more credence for a bigger deal somewhere else- USA, China, Europe or MPS. It delays bigger deal and revenue but might be a less dilutive path. Not a lot of faith in PR ability to make the right move. Unless they really do have a deal pending, my fear is he goes for broke and we get another value destructive CR should he continue with the FDA. The market at present seems to be anticipating another CR. I hope they navigate the next few months carefully and with a lot of wisdom and advice (perhaps from another Chair??).
PAR Price at posting:
25.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)